Novo Nordisk A/S Sponsored ADR logo

Novo Nordisk A/S Sponsored ADR (NVO)

Market Closed
27 Feb, 20:00
NYSE NYSE
$
37. 45
-0.17
-0.45%
$
210.86B Market Cap
48.26 P/E Ratio
0.56% Div Yield
24,007,597 Volume
0 Eps
$ 37.62
Previous Close
Day Range
37.33 37.86
Year Range
37.31 91.9
Want to track NVO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NVO earnings report is expected in 66 days (6 May 2026)
Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing

Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing

Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.

Foxbusiness | 1 year ago
Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk gains approval in China for blockbuster drug Wegovy. More than 11% of all adults in China live with diabetes - more than any other country in the world. Both Eli Lilly and Novo Nordisk are disrupting the diet industry with their GLP-1 drugs, offering the potential for significant growth in the future.

Seekingalpha | 1 year ago
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.

Zacks | 1 year ago
Novo Nordisk Rises as Wegovy Is Approved in China

Novo Nordisk Rises as Wegovy Is Approved in China

American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) rose Tuesday on the New York Stock Exchange (NYSE) after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China.

Investopedia | 1 year ago
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Zacks | 1 year ago
Novo Nordisk gains approval to sell weight-loss drug Wegovy in China

Novo Nordisk gains approval to sell weight-loss drug Wegovy in China

Novo Nordisk has gained approval to start marketing its blockbuster weight-loss drug Wegovy in China, opening the door for the Danish pharmaceutical giant to further boost sales of the medicine that has transformed it into Europe's most valuable company.

Marketwatch | 1 year ago
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug

NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug

Novo Nordisk (NYSE: NVO ) stock rose on news that China has approved its weight loss drug Wegovy and that the drugmaker will invest $4.1 billion into expanding its U.S. production capacity. The expansion will be built in North Carolina and is part of a $11 billion global production push.

Investorplace | 1 year ago
Novo Nordisk wins approval for its weight-loss drug from China

Novo Nordisk wins approval for its weight-loss drug from China

Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy.  Year-to-date, shares of the pharmaceutical giant are now up a whopping 45%.

Invezz | 1 year ago
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages

Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages

Ozempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market, but the company told Forbes it will only launch there once it could guarantee supplies for those already taking it as shortages plague the U.S. market and elsewhere.

Forbes | 1 year ago
Novo Nordisk's Wegovy weight loss drug approved in China

Novo Nordisk's Wegovy weight loss drug approved in China

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management. The approval opens up the blockbuster drug for sale for those with obesity and at least one weight-related comorbidity.

Cnbc | 1 year ago
Ozempic maker Novo Nordisk to spend $4.1bn on North Carolina facility

Ozempic maker Novo Nordisk to spend $4.1bn on North Carolina facility

Novo Nordisk (NYSE:NVO) is investing $4.1 billion to expand its US manufacturing, focusing on its high-demand weight-loss drugs, Ozempic and Wygovy. The investment will fund a new 1.4 million square foot plant near Raleigh, North Carolina, doubling the site's size.

Proactiveinvestors | 1 year ago
Novo Nordisk says Semaglutide approved for long-term weight management in China

Novo Nordisk says Semaglutide approved for long-term weight management in China

Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.

Reuters | 1 year ago
Loading...
Load More